Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) generates news across animal health, regenerative medicine and veterinary-focused artificial intelligence. The company, together with its subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., reports on developments in its veterinary medical devices, platelet-rich plasma products and AI platforms designed for companion animals and horses.
News coverage for PetVivo often highlights updates on its lead products SPRYNG® with OsteoCushion® technology and PrecisePRP®, including distribution agreements, clinical adoption by veterinary practices and educational initiatives such as continuing education courses and conference presentations. Press releases also describe how these products are promoted through vendor partnerships and distributor networks, as well as their use in managing osteoarthritis, lameness and other joint-related conditions in cats, dogs and horses.
Another key theme in PetVivo news is its expansion into veterinary AI and digital platforms. Announcements have detailed the launch of the PetVivo.ai platform, an AI-powered system intended to improve veterinary client acquisition and engagement through multiple specialized AI agents. Additional releases cover PetVivo’s exclusive 10-year white-label licensing agreement for the Agentic Pet AI framework, publication of a technical whitepaper validating this multi-agent architecture and plans for dual-platform launches that connect pet parents with veterinary practices.
Investors and veterinary professionals following PETV news can also see updates on strategic alliances, board appointments, investor conference presentations and financial results. Earnings-related releases describe revenue trends, product mix developments and distribution expansion, while corporate announcements provide insight into capital structure actions and governance changes. For ongoing context around PetVivo’s products, partnerships and AI initiatives, this news feed offers a centralized view of the company’s public disclosures.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) is showcasing its innovative product, SPRYNG™ with OsteoCushion™ Technology, at the Veterinary Orthopedic Society Annual Conference from March 11-18, 2023, in Big Sky, Montana. SPRYNG™ is an injection-based treatment targeting lameness and joint issues like osteoarthritis in companion animals. CEO John Lai expressed excitement for the opportunity to connect with veterinary professionals. Additionally, Dr. Erik Kleeman will present research on intra-articular injections for dogs with cruciate ligament injuries on March 17, 2023. PetVivo focuses on developing advanced biomedical devices for animal care, with a pipeline of seventeen products and nineteen patents.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) announced its participation in the Western Veterinary Conference from February 19-22, 2023, at Mandalay Bay, Las Vegas. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for managing joint-related issues in pets, particularly osteoarthritis. The WVC is a key event, generally attracting over 15,000 veterinary professionals. CEO John Lai expressed optimism about discussing SPRYNG's benefits with veterinarians, evidencing the company's commitment to enhancing the quality of life for companion animals.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) reported significant financial results for Q3 of fiscal 2023, highlighting revenues of $510,109, a substantial increase from $51,004 in Q3 2022. This growth is attributed to the commercialization of its product, Spryng™ with OsteoCushion™ Technology, with $456,502 stemming from shipments to distributor MWI Animal Health. Despite increased revenues, the company's net loss for the quarter rose to $2,311,618 or ($0.23) per share, compared to ($0.17) per share last year, driven by increased operating expenses totaling $2,605,240.
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will report its financial results on February 9, 2023, after market close. A conference call is scheduled for 4:00 p.m. CT (5:00 p.m. ET) to discuss these results. Investors can access the live webcast through the company's Investor Relations website.
PetVivo focuses on innovative medical therapeutics for animals, with a product pipeline of seventeen offerings and nineteen patents protecting its technologies. The lead product, SPRYNG™ with OsteoCushion™ technology, targets joint-related afflictions in dogs and horses.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) is set to exhibit its innovative product, Spryng with OsteoCushion Technology, at the Minnesota Veterinary Medical Association Annual Meeting from February 2-4, 2023, in Minneapolis. Spryng is designed to manage lameness and joint issues like osteoarthritis in companion animals through an injectable veterinary medical device made from natural components. The company aims to leverage human therapies for animal treatment, showcasing a robust pipeline protected by nineteen patents. CEO John Lai invites attendees to visit their booth for insights on this veterinary advancement.
PetVivo Holdings, focused on companion animal health, will participate in the virtual Lytham Partners Investor Select Conference on January 31, 2023. CEO John Lai will present the company's innovative product, Spryng with OsteoCushion Technology, which is designed to manage joint issues like osteoarthritis in pets through an injectable delivery system. The conference will also include one-on-one meetings with management for investors. PetVivo has developed a range of biomedical devices and holds 19 patents to protect its technology. The company aims to accelerate the commercialization of its veterinary products, which are available for sale.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has announced its participation in the 2023 Lake Tahoe Equine Conference from January 23-27, 2023, held at Hyatt Lake Tahoe, Nevada. The company aims to showcase its innovative product, Spryng™ with OsteoCushion™ Technology, which is designed to manage lameness and joint issues in companion animals. This injectable veterinary medical device combines extracellular matrix particles to support damaged cartilage and address tissue defects. PetVivo's strategy focuses on leveraging human therapies for animal treatments, accelerating revenue timelines, and capitalizing on a portfolio of nineteen patents to protect its innovative biomaterials and methods.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will showcase its innovative veterinary medical device, Spryng™, at the 2023 FAEP Ocala Equine Conference on January 21-22, 2023, in Ocala, FL. The company aims to network with equine industry leaders to enhance its OsteoCushion™ Technology, which supports joint health in companion animals, particularly for osteoarthritis treatment. Spryng™ utilizes an injectable formulation of micronized extracellular matrix particles to assist in managing lameness and joint issues. PetVivo's strategy involves leveraging human medical innovations for quicker veterinary solutions.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a lease for 14,000 sq. ft. in Edina, Minnesota, to expand its production capacity for Spryng™ with OsteoCushion™ Technology and other medical devices. This facility will feature clean rooms for large-scale production, slated to begin in August 2023. CEO John Lai emphasized this expansion aims to meet global demand for Spryng™, a veterinary device addressing lameness in animals. The company holds nineteen patents for its products, reinforcing its commitment to innovative veterinary medical solutions.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced its participation in the Veterinary Meeting & Expo, occurring from January 14-18, 2023, in Orlando, FL. The company will showcase its lead product, Spryng™ with OsteoCushion™ Technology, designed for managing joint afflictions in companion animals. This conference is the largest veterinary event in the U.S., attracting over 10,000 attendees. CEO John Lai expressed enthusiasm for networking with industry leaders to advance the commercialization of veterinary medical devices.
FAQ
What is the current stock price of Petvivo Hldgs (PETV)?
What is the market cap of Petvivo Hldgs (PETV)?
